UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
November 13, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
|
Form
20-F x
|
Form
40-F o
|
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes o
|
No x
|
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
A
copy of the attached letter was posted to shareholders holding ordinary shares
in the UK and Channel Islands registrar.
November
13, 2007
To
Ordinary Shareholders and Holders of Depository Interests
Re:
Shareholders’ Choices Following De-Listing of XTL Biopharmaceuticals Ltd. (“XTL”
or the “Company”) Ordinary Shares from the London Stock Exchange
(“LSE”)
Dear
Investor:
Background
On
October 31, 2007 an announcement was issued by XTL that the Company’s ordinary
shares have been delisted from the Official List of the United Kingdom Listing
Authority, pursuant to the October 2, 2007 vote at the Company’s Extraordinary
General Meeting.
Post
cancellation of the listing on the LSE
Following
the cancellation of the LSE listing of the Company's ordinary shares,
shareholders may continue to hold their certificated ordinary shares. Holders
of
depository interests may also continue to hold their depository
interests.
Alternatively
shareholders may deposit their ordinary shares with the Company’s depositary
bank, The Bank of New York, in exchange for American Depositary Receipts, or
ADRs, which are traded on NASDAQ, or deposit their ordinary shares with the
Company’s Israeli depository agent, the Registration Company of Bank Hapoalim
Ltd., and trade their ordinary shares on the Tel Aviv Stock Exchange
(“TASE”).
ADR
The
Bank
of New York will issue ADRs representing American Depositary Shares, or ADSs,
if
shareholders or their broker deposit ordinary shares with The Bank of New York’s
Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London
office of The Bank of New York. One ADR will represent an ownership interest
in
ten of the Company’s Ordinary Shares.
XTL
has further announced that issuances of ADRs by The Bank of New York will be
processed free of the customary charges of The Bank of New York for an
additional month, through November 30, 2007.
Interested
investors should contact their brokers to discuss the waived fee and, should
they have any questions, can contact The Bank of New York in either London
or
New York as follows:
|
London
|
or
|
New
York
|
|
Mark
Lewis
|
Jason
Paltrowitz
|
|
|
Vice
President
|
Vice
President
|
|
|
Tel
+ 44 207.964.6089
|
Tel
+1.212.815.2077
|
|
|
Fax
+ 44 207.964.6024
|
Fax
+1.212.815.3004
|
|
|
marlewis@bankofny.com
|
jpaltrowitz@bankofny.com
|
Ordinary
Shares on TASE
The
Company’s ordinary shares are traded on the TASE. With the appropriate bank or
brokerage account in Israel, investors looking to trade their ordinary shares
on
TASE should contact their Israeli bank or broker. In order to do so,
shareholders, or their brokers, are required to deposit the certificate
representing their ordinary shares together with a duly signed and executed
transfer form with the Company’s Israeli depository agent, the Registration
Company of Bank Hapoalim Ltd. Should investors have any questions, they may
also
contact Computershare as follows:
|
UK
|
or
|
Channel
Islands
|
|
John
Gorski
|
Gemma
Barette
|
|
|
Manager
- Global Transaction Unit
|
Team
Leader
|
|
|
Tel:
+ 44.117.305.1075
|
Tel:
+ 44.1534.825294
|
|
|
Fax:
+ 44.870.889.3120
|
Fax:
+ 44.1534.825315
|
|
|
John.gorski@computershare.co.uk
|
Gemma.barette@computershareci.com
|
Sincerely,
/s/
Bill
Kessler
Bill
Kessler
Director
of Finance
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
||
|
Date:
November 13, 2007
|
By:
|
/s/
Ron Bentsur
|
|
Ron
Bentsur
|
||
|
Chief
Executive Officer
|
||